188 related articles for article (PubMed ID: 29574193)
1. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
2. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
Li CSW; Sweeney K; Cronenberger C
Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
6. Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection.
Peraza MA; Hurst S; Huang W; Buetow BS; Lickteig AJ; Lavach JD; Frost DF; Collins ME; Sellers RS; Matsumoto Smith D
J Ocul Pharmacol Ther; 2023 Apr; 39(3):215-224. PubMed ID: 36880872
[No Abstract] [Full Text] [Related]
7. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
[TBL] [Abstract][Full Text] [Related]
8. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical pharmacology and toxicology studies of bevacizumab biosimilar LY01008.
Guangying D; Shuzhi M; Xiaoyin Z; Pengfei Y; Xin Y; Liang Y; Xin S; Baiping S; Changlin D; Hongbo W; Jingwei T
Eur J Pharmacol; 2022 Dec; 936():175383. PubMed ID: 36347321
[TBL] [Abstract][Full Text] [Related]
10. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
Hardiansyah D; Ng CM
Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
[TBL] [Abstract][Full Text] [Related]
11. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes.
Julien S; Biesemeier A; Schraermeyer U
Br J Ophthalmol; 2013 Apr; 97(4):511-7. PubMed ID: 23355530
[TBL] [Abstract][Full Text] [Related]
14. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts.
Kim EK; Kang SW; Kim JY; Min K; Kim TI
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3922-31. PubMed ID: 23640039
[TBL] [Abstract][Full Text] [Related]
15. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
Li M; An W; Wang L; Zhang F; Li J; Zhang Y; Li Y; Li H; Ren W; Zhao R; Xia C; Sun L
J Immunol Methods; 2019 Jun; 469():42-46. PubMed ID: 30943379
[TBL] [Abstract][Full Text] [Related]
16. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Goyal P; Vats B; Subbarao M; Honnappa CG; Kabadi P; Rohil S; Bera A; Mehta GR; Pai H; Adhikari L; Tagore R; Sharma S; Venkatachala R; Nair P; Annegowda S; Sahu A; Trivedi S; Shastri N; Gokhale Y; Thomas R; Thakur A; Mohan D; Rao K U; Melarkode R; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):271-298. PubMed ID: 34465264
[TBL] [Abstract][Full Text] [Related]
17. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
18. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
19. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
20. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
